Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;35(7):2237-2239.
doi: 10.1053/j.jvca.2020.10.040. Epub 2020 Oct 24.

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series

Stephen Su Yang  1 , Rosa Boudjemai  2 , Jed Lipes  3
Affiliations

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series

Stephen Su Yang et al. J Cardiothorac Vasc Anesth. 2021 Jul.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
Scatter plot with line illustrating C-reactive protein level versus day relative to Tocilizumab administration.
Fig 2
Fig 2
Scatter plot with line illustrating PaO2/FiO2 level versus day relative to Tocilizumab administration.
See this image and copyright information in PMC

References

    1. Yang SS, Lipes J. Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: A limited case series. Can J Anaesth. 2020:1–3. - PMC - PubMed
    1. Zhang C, Wu Z, Li JW, et al. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55 - PMC - PubMed
    1. Hoiland RL, Stukas S, Cooper J, et al. Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome. Br J Haematol. 2020;190:e150–e154. - PMC - PubMed
    1. Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol. 2020;129 - PMC - PubMed
    1. Rojas-Marte GR, Khalid M, Mukhtar O, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab - a case- controlled study. QJM. 2020;113:546–550. - PMC - PubMed

LinkOut - more resources